Stocks Comparison
GE HealthCare Technologies vs Nano-X Imaging: revenue, profit, margins and growth compared
GE HealthCare Technologies brought in $20.6B of revenue in fiscal 2025, Nano-X Imaging $13M in fiscal 2025. Revenue changed by +4.8% at GE HealthCare Technologies and +15.4% at Nano-X Imaging on the year before, so Nano-X Imaging grew faster. GE HealthCare Technologies kept 10.1% of its revenue as net profit, Nano-X Imaging -576.1%. Free cash flow was $1.5B at GE HealthCare Technologies and -$45M at Nano-X Imaging.
Side by side, latest fiscal year
| GEHC | NNOX | |
|---|---|---|
| Fiscal year ended | FY2025 (December 31, 2025) | FY2025 (December 31, 2025) |
| Revenue | $20.6B | $13M |
| Revenue growth | +4.8% | +15.4% |
| Net income | $2.1B | -$75M |
| Net margin | 10.1% | -576.1% |
| Free cash flow | $1.5B | -$45M |
| Free cash flow margin | 7.3% | -345.6% |
| Earnings per share (diluted) | $4.55 | -$1.16 |
| Cash | $4.5B | $49.2M |
| Debt | $10B | n/a |
| Price to earnings | 14.6 | n/a |
| Market value | $30.1B | $50.3M |
| Dividend yield | 0.21% | n/a |
| Rank by revenue in sector | #29 of 523 · Health care | #427 of 523 · Health care |
Over the years
Questions about GE HealthCare Technologies and Nano-X Imaging
Which is bigger by revenue, GE HealthCare Technologies or Nano-X Imaging?
GE HealthCare Technologies is bigger by revenue: $20.6B in fiscal 2025, against $13M for Nano-X Imaging in fiscal 2025.
Which keeps more of its revenue as profit, GE HealthCare Technologies or Nano-X Imaging?
GE HealthCare Technologies had a net margin of 10.1% in fiscal 2025; Nano-X Imaging had -576.1% in fiscal 2025.
Which grew revenue faster, GE HealthCare Technologies or Nano-X Imaging?
In their latest fiscal years revenue changed by +4.8% at GE HealthCare Technologies and +15.4% at Nano-X Imaging.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.